Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-cell Targets in Human IDH-Mutant Glioma
click here for abstract.
"By analyzing the repertoire of T-cell target antigens in IDH mut glioma patients, we identified five novel immunogenic TAAs [tumor associated antigens] and confirmed their expression on IDH mut tumors and GSCs [glioma stem cells]."
Don't know where else to post this:
ReplyDeleteSuppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
https://www.nature.com/articles/s41591-018-0095-6
Sci-Hub link (working at the moment):
https://sci-hub.tw/https://www.nature.com/articles/s41591-018-0095-6
Another evidence that IDH1 mutation is immunosuppresive. In discussion, the authors write: "Moreover, clinical studies applying checkpoint
blockade or specific immune interventions such as IDH1R132H-
specific vaccines may be more effective when combined with IDH
inhibitors."
I hope there will be some trials combining IDH1 inhibitors and immunotherapy in near future.
Me too, I've been waiting for such trials for over a year, since this was published:
Deletehttps://www.ncbi.nlm.nih.gov/pubmed/28319047
Here's another one:
Deletehttp://sci-hub.tw/http://clincancerres.aacrjournals.org/content/early/2018/07/13/1078-0432.CCR-17-3855.full-text.pdf
The oncometabolite D-2-hydroxyglutarate is an intercellular mediator in IDH-mutant gliomas that inhibits both complement and T cells